Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis

被引：0

作者：

James Yarmolinsky

Emmanouil Bouras

Andrei Constantinescu

Kimberley Burrows

Caroline J. Bull

Emma E. Vincent

Richard M. Martin

Olympia Dimopoulou

Sarah J. Lewis

Victor Moreno

Marijana Vujkovic

Kyong-Mi Chang

Benjamin F. Voight

Philip S. Tsao

Marc J. Gunter

Jochen Hampe

Andrew J. Pellatt

Paul D. P. Pharoah

Robert E. Schoen

Steven Gallinger

Mark A. Jenkins

Rish K. Pai

Dipender Gill

Kostas K. Tsilidis

机构：

[1] University of Bristol,MRC Integrative Epidemiology Unit

[2] Bristol Medical School,Population Health Sciences

[3] University of Bristol,Department of Hygiene and Epidemiology

[4] University of Ioannina Medical School,School of Translational Health Sciences

[5] University of Bristol,NIHR Bristol Biomedical Research Centre

[6] University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol,Biomarkers and Susceptibility Unit, Oncology Data Analytics Program

[7] Catalan Institute of Oncology (ICO),Colorectal Cancer Group, ONCOBELL Program

[8] L’Hospitalet de Llobregat,Department of Clinical Sciences, Faculty of Medicine

[9] Bellvitge Biomedical Research Institute (IDIBELL),Department of Medicine

[10] L’Hospitalet de Llobregat,Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine

[11] Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP),Department of Genetics

[12] University of Barcelona,Institute of Translational Medicine and Therapeutics

[13] Corporal Michael J. Crescenz VA Medical Center,Department of Medicine

[14] University of Pennsylvania Perelman School of Medicine,Stanford Cardiovascular Institute

[15] University of Pennsylvania,Nutrition and Metabolism Section, International Agency for Research on Cancer

[16] Perelman School of Medicine,Department of Medicine I

[17] University of Pennsylvania,Department of Public Health and Primary Care

[18] University of Pennsylvania,Department of Medicine and Epidemiology

[19] VA Palo Alto Epidemiology Research and Information Center for Genomics,Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital

[20] VA Palo Alto Health Care System,Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health

[21] Stanford University School of Medicine,Department of Laboratory Medicine and Pathology

[22] Stanford University School of Medicine,Department of Epidemiology and Biostatistics, School of Public Health

[23] World Health Organization,undefined

[24] University Hospital Dresden,undefined

[25] Technische Universität Dresden (TU Dresden),undefined

[26] University of Texas MD Anderson Cancer Center,undefined

[27] University of Cambridge,undefined

[28] University of Pittsburgh Medical Center,undefined

[29] University of Toronto,undefined

[30] The University of Melbourne,undefined

[31] Mayo Clinic Arizona,undefined

[32] Imperial College London,undefined

[33] St Mary’s Campus,undefined

来源：

Diabetologia | 2023年 / 66卷

关键词：

ABCC8; Breast cancer; Colorectal cancer; GLP1R; Glucose-lowering drug targets; Mendelian randomisation; PPARG; Prostate cancer;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1481 / 1500

页数：19

共 50 条

[1] Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis
Yarmolinsky, James
Bouras, Emmanouil
Constantinescu, Andrei
Burrows, Kimberley
Bull, Caroline J.
Vincent, Emma E.
Martin, Richard M.
Dimopoulou, Olympia
Lewis, Sarah J.
Moreno, Victor
Vujkovic, Marijana
Chang, Kyong-Mi
Voight, Benjamin F.
Tsao, Philip S.
Gunter, Marc J.
Hampe, Jochen
Pellatt, Andrew J.
Pharoah, Paul D. P.
Schoen, Robert E.
Gallinger, Steven
Jenkins, Mark A.
Pai, Rish K.
Gill, Dipender
Tsilidis, Kostas K.
DIABETOLOGIA, 2023, 66 (08) : 1481 - 1500
[2] Genetically Proxied Glucose-lowering Drug Target and Risk of Immune Mediated Inflammatory Disease: A Mendelian Randomization Study
Wu, Dongze
Jin, Yingzhao
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4152 - 4154
[3] Genetically Proxied Antiplatelet Drug Target Perturbation and Risk of Aneurysmal Subarachnoid Hemorrhage: A Mendelian Randomization Analysis
Fan, Yu-xiang
Yang, Cheng-bin
Song, Zi-hao
Yang, Xu
Ma, Yong-jie
Zhang, Hong-qi
WORLD NEUROSURGERY, 2025, 196
[4] Association of glucose-lowering drug target and risk of gastrointestinal cancer: a mendelian randomization study
Yi Yang
Bo Chen
Chongming Zheng
Hao Zeng
Junxi Zhou
Yaqing Chen
Qing Su
Jingxian Wang
Juejin Wang
Yurong Wang
Hongli Wang
Ruxue Jin
Zhiyuan Bo
Gang Chen
Yi Wang
Cell & Bioscience, 14
[5] Association of glucose-lowering drug target and risk of gastrointestinal cancer: a mendelian randomization study
Yang, Yi
Chen, Bo
Zheng, Chongming
Zeng, Hao
Zhou, Junxi
Chen, Yaqing
Su, Qing
Wang, Jingxian
Wang, Juejin
Wang, Yurong
Wang, Hongli
Jin, Ruxue
Bo, Zhiyuan
Chen, Gang
Wang, Yi
CELL AND BIOSCIENCE, 2024, 14 (01):
[6] Genetically proxied ketohexokinase function and risk of colorectal cancer: a Mendelian randomisation study
Buziau, Amee M.
Law, Philip J.
Blokland, Gabriella
Schalkwijk, Casper
Scheijen, Jean
Simons, Pomme
van der Kallen, Carla
Eussen, Simone
Dagnelie, Pieter C.
van Greevenbroek, Marleen
Houlston, Richard S.
Wesselius, Anke
Went, Molly
Stehouwer, Coen
Brouwers, Martijn C. G. J.
GUT, 2023, 72 (03) : 604 - 606
[7] Genetically Proxied Lipid-Lowering Drug Target Perturbation and Ischemic Stroke Risk in European and African Ancestry Individuals: Mendelian Randomization Study
Soremekun, Opeyemi
Mhlongwe, Thobeka
Kirabo, Gloria
Akinyele, Callistus
Chikowore, Tinashe
Fatumo, Segun
Gill, Dipender
STROKE, 2024, 55 (07) : e185 - e186
[8] Genetically proxied lean mass and risk of Alzheimer's disease: mendelian randomisation study
Daghlas, Iyas
Nassan, Malik
Gill, Dipender
BMJ MEDICINE, 2023, 2 (01):
[9] Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study
Fang, Si M.
Yarmolinsky, James
Gill, Dipender R.
Bull, Caroline G.
Perks, Claire
Smith, George Davey
Gaunt, Tom
Richardson, Tom
PLOS MEDICINE, 2023, 20 (01)
[10] Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of pancreatic cancer: a mendelian randomization analysis
Yao, Zehui
Qin, Dailei
Cao, Jianzhong
Gao, Chun
Xi, Pu
Li, Shengping
Wei, Ran
BMC CANCER, 2025, 25 (01)

← 1 2 3 4 5 →